NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma

BACKGROUND: A randomized, phase II, placebo-controlled, and blinded clinical trial (NCT01062425) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, versus placebo in combination with radiation and temozolomide in n...

Descripción completa

Detalles Bibliográficos
Autores principales: Batchelor, Tracy T, Won, Minhee, Chakravarti, Arnab, Hadjipanayis, Costas G, Shi, Wenyin, Ashby, Lynn S, Stieber, Volker W, Robins, H Ian, Gray, Heidi J, Voloschin, Alfredo, Fiveash, John B, Robinson, Clifford G, Chamarthy, UshaSree, Kwok, Young, Cescon, Terrence P, Sharma, Anand K, Chaudhary, Rekha, Polley, Mei-Yin, Mehta, Minesh P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660192/
https://www.ncbi.nlm.nih.gov/pubmed/38024244
http://dx.doi.org/10.1093/noajnl/vdad116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660192/
https://www.ncbi.nlm.nih.gov/pubmed/38024244
http://dx.doi.org/10.1093/noajnl/vdad116

Ejemplares similares